Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study.

CONCLUSIONS: With up to 8 years of follow-up, sustained responses and long-term tolerability of single-agent ibrutinib were observed with treatment of first-line or relapsed/refractory CLL/SLL, including high-risk CLL/SLL.
PMID: 32209572 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 23, 2020 Category: Cancer & Oncology Authors: Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger J, Blum KA, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S Tags: Clin Cancer Res Source Type: research